Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KALA | US
-0.15
-2.82%
Healthcare
Biotechnology
30/06/2024
17/10/2024
5.11
5.25
5.30
4.95
Kala Pharmaceuticals Inc. a biopharmaceutical company focuses on the discovery development and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012 which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Hanes Newco Inc. and changed its name to Kala Pharmaceuticals Inc. in December 2009. Kala Pharmaceuticals Inc. was incorporated in 2009 and is headquartered in Watertown Massachusetts.
View LessValue Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
20.4%1 month
35.3%3 months
45.8%6 months
77.0%-
-
1.77
2.68
0.60
-0.16
0.04
-
-40.98M
28.02M
28.02M
-
-
-
-100.00
-248.11
2.43
0.68
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.45
Range1M
1.10
Range3M
2.83
Rel. volume
0.97
Price X volume
64.16K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
DarT Bioscience Inc | DARE | Biotechnology | 3.6 | 30.77M | 0.56% | 0.10 | 218.34% |
Anthem Inc. CORP UNIT 050118 | ANTX | Biotechnology | 1.03 | 30.74M | -2.83% | n/a | 0.00% |
BriaCell Therapeutics Corp. Common Shares | BCTX | Biotechnology | 0.845 | 30.28M | 0.80% | n/a | 0.00% |
Fortress Biotech Inc | FBIOP | Biotechnology | 5.6 | 30.06M | 8.11% | n/a | 494.61% |
Marker Therapeutics Inc | MRKR | Biotechnology | 3.25 | 29.00M | -7.67% | n/a | 0.00% |
ImmuCell Corporation | ICCC | Biotechnology | 3.625 | 28.39M | 1.83% | n/a | 67.52% |
Mawson Infrastructure Group Inc. Common Stock | MIGI | Biotechnology | 1.45 | 26.90M | -0.68% | n/a | 571.64% |
Akari Therapeutics Plc | AKTX | Biotechnology | 2.21 | 26.84M | -12.30% | n/a | -27.01% |
Common Stock | NRBO | Biotechnology | 3.16 | 26.82M | 6.76% | n/a | 0.90% |
PLUR | PLUR | Biotechnology | 4.8089 | 26.31M | -2.85% | n/a | 30845.83% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.16 | 0.53 | Cheaper |
Ent. to Revenue | 0.04 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 1.77 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 45.85 | 72.92 | Lower Risk |
Debt to Equity | 2.68 | -1.24 | Expensive |
Debt to Assets | 0.60 | 0.25 | Expensive |
Market Cap | 28.02M | 3.78B | Emerging |